+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P06690(KAT6A Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of KAT6A Antibody**

KAT6A (lysine acetyltransferase 6A), also known as MOZ or MYST3. is a member of the MYST family of histone acetyltransferases (HATs). It plays a critical role in regulating gene expression by acetylating histones, particularly histone H3. to modulate chromatin structure and transcriptional activity. KAT6A is essential for normal embryonic development, hematopoiesis, and cell cycle control. Dysregulation or mutations in KAT6A are linked to developmental disorders, such as autosomal dominant KAT6A syndrome (also called Arboleda-Tham syndrome), characterized by intellectual disability, congenital anomalies, and growth delays, as well as various cancers, including acute myeloid leukemia (AML) and other malignancies.

KAT6A antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect KAT6A protein levels in tissues or cell lines. Researchers also employ KAT6A antibodies to explore its interactions with partner proteins (e.g., BRPF1/2/3. ING5. and MEAF6) and its role in chromatin remodeling complexes. Given its association with cancer and developmental diseases, KAT6A-targeted research holds therapeutic potential, driving the demand for reliable antibodies to advance mechanistic and translational studies.